<DOC>
	<DOCNO>NCT02439697</DOCNO>
	<brief_summary>This prospective single-arm open-labeled cohort study dialysis patient conversion Aranesp® NESP® treatment anemia . The primary outcome study haemoglobin level conversion NESP® 6 month . Secondary outcome include variability haemoglobin level , average weekly dose erythropoietin , safety profile NESP® , patient ' subjective assessment fatigue injection pain conversion .</brief_summary>
	<brief_title>A Cohort Study Conversion From Aranesp® NESP® Treatment Anemia Dialysis Patients</brief_title>
	<detailed_description>Currently Hong Kong , Aranesp® , manufacture Amgen® available Darbepoetin alpha license . NESP® , Darbepoetin alpha agent manufacture Kirin® , replace Aranesp®.It important evaluate therapeutic equivalence two agent , efficacy , tolerability safety profile treatment anemia dialysis patient . Moreover , new maximum preparation NESP 120® microgram available replace Aranesp® 100 microgram prefilled syringe cost . This large Darbepoetin alpha preparation may allow extension dose interval . This may subsequently allow cost save good convenience medical staff patient . The objective project : 1 . To investigate effectiveness NESP® achieve stable anemia control chronic dialysis patient dose conversion Aranesp® 2 . To investigate effectiveness increase dose interval NESP® ( maintain total dose ) sustain stable anemia control chronic dialysis patient 3 . To explore possibility cost save administer large dose NESP® extend interval Patients divide 3 group . Group A . Same dose conversion group • Patients stable low dose Aranesp® ( 20mcg preparation 40mcg every 2 week less ) convert dose NESP® Group B . Attempt extension dose interval high dose NESP® preparation • Patients stable dose Aranesp® convert high dose preparation NESP® ( 40 120 mcg preparation ) extend dose interval . Group C. Attempt dosage save 120 mcg preparation • Patients Aranesp® 100mcg switch NESP® 120mcg preparation slight increase dose interval</detailed_description>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Darbepoetin alfa</mesh_term>
	<criteria>Adult Chinese patient ( age great equal 18 ) longterm dialysis least 3 month Aranesp® treatment least 3 month stable hemoglobin level within range 9 to12 g/dL , stable dose Aranesp® within past 2 month . Minimum weekly kT/V 1.7 peritoneal dialysis patient 1.2 per haemodialysis session haemodialysis patient Able give inform consent Presence thalassaemia haematological disease severe hyperparathyroidism ( PTH &gt; 90 pmol/L ) iron , vitamin B12 folate deficiency uncontrolled malignancy active blood loss hemolysis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>